MeSH tree: D12.776.124.486.485.114.224.060.375
In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a "master regulator" gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving ...
Apr 3, 2025
0
20
A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in patients with recurrent ovarian ...
Dec 13, 2024
0
50
A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer.
Sep 17, 2024
0
39
SOLARIS (Alliance A021703), a multicenter, double-blind, randomized Phase III clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition ...
Sep 16, 2024
0
57
A cancer study has found that certain gut bacteria may influence whether or not a patient's immune system is successful in fighting mesothelioma, an aggressive form of cancer.
Sep 5, 2024
0
41
A University at Buffalo researcher who is a leading expert on retinopathy of prematurity (ROP) has published a study that could change the standard of care for the condition. ROP occurs in low birthweight premature babies; ...
May 13, 2024
0
47
Patient prognosis and treatment response prediction are key factors in treating ovarian cancer, which is characterized by the lowest survival rate among gynecological cancers. Consequently, there is strong demand for a more ...
Apr 15, 2024
0
37
What could cancer teach us about tuberculosis? That's a question Meenal Datta has been chasing since she was a graduate student.
Mar 25, 2024
0
46
A recent study opens up a novel approach for improving personalized treatments for patients with glioblastoma, one of the most aggressive types of cancer in existence today.
Jan 31, 2024
0
30
For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS), ...
Jan 29, 2024
0
27
